Showing 2251-2260 of 2527 results for "".
- Octane Aesthetics Tech Forum Panelists React to FDA Approval of Oral Semaglutidehttps://modernaesthetics.com/news/octane-aesthetics-tech-forum-panelists-react-to-fda-approval-of-oral-semaglutide/2485572/At the 2026 Octane Aesthetics Tech Forum, panelists weighed in on the recent FDA approval of oral semaglutide, offering a mix of cautious optimism and clinical realism. While the approval marks a milestone in expanding GLP-1 receptor agonist (RA) access, most experts on the panel said oral versio
- Octane Aesthetics Tech Forum: Panelists Discuss Innovation in Hair Loss Delivery, Regulationhttps://modernaesthetics.com/news/octane-aesthetics-tech-forum-panelists-discuss-innovation-in-hair-loss-delivery-regulation/2485561/The future of hair restoration may be rooted in regenerative science, but panelists at the Octane Aesthetics Tech Forum agree: the real-world success of these advances hinges on how treatments are delivered and how they’re regulated. Speaking during the “Hiding in the Shadows of H
- Candela Launches Glacē™ System at IMCAS Paris, Expands Portfolio with Matrix™ and Vbeam® Prohttps://modernaesthetics.com/news/candela-launches-glace-system-at-imcas-paris-expands-portfolio-with-matrix-and-vbeam-pro/2485539/Candela debuted its latest innovation, the Glacē™ System, during the 2026 IMCAS World Congress in Paris, marking the European launch of a platform designed to elevate facial skin treatments across aesthetic and medical settings. The system, which offers both standalone and adjunctive skin purific
- Octane Aesthetics Tech Forum: 3 Big Trends from GuidePoint Qsight’s 2025 Market Analysishttps://modernaesthetics.com/news/octane-aesthetics-tech-forum-3-big-trends-from-guidepoint-qsights-2025-market-analysis/2485514/At the 2026 Octane Aesthetic Tech Forum, Erik Haines, Managing Director of Guidepoint Qsight, presented a data-rich snapshot of the state of the medical aesthetics industry. Drawing from over $17 billion in transactional data across 45,000 aesthetic practices and millions of patient records, Hain
- Octane Aesthetics Tech Forum: GLP-1 Receptor Agonists Are Reshaping Consumer Behavior and Aesthetic Business Modelshttps://modernaesthetics.com/news/octane-aesthetics-tech-forum-glp-1-receptor-agonists-are-reshaping-consumer-behavior-and-aesthetic-business-models/2485431/The rise of GLP-1 receptor agonist (GLP-1RA) medications is doing more than transforming bodies; it is reshaping the very business of aesthetics. At the 2026 Octane Aesthetics Tech Forum, panelists described how GLP-1RAs are influencing patient behavior, redefining value propositions, and catalyz
- Podium Introduces Artificial Intelligence Operating System Designed for Aesthetic Practiceshttps://modernaesthetics.com/news/podium-introduces-artificial-intelligence-operating-system-designed-for-aesthetic-practices/2485420/Podium has announced the launch of an artificial intelligence (AI)–driven operating system designed specifically for aesthetic practices, positioning the platform as a unified alternative to the fragmented software ecosystems common in cosmetic dermatology practices. The company describes the pro
- skinbetter science® Marks 10 Years of AlphaRet® Technology in Retinoid-AHA Skincarehttps://modernaesthetics.com/news/skinbetter-science-marks-10-years-of-alpharet-technology-in-retinoid-aha-skincare/2485358/skinbetter science® is marking the 10-year anniversary of its proprietary AlphaRet® technology, introduced in 2016 as one of the first topical skincare formulas to combine a retinoid with an alpha hydroxy acid (AHA). The combination, used in the flagship AlphaRet Overnight Cream, was designed to
- FDA Approves RHA® Dynamic Volume for Midface Augmentationhttps://modernaesthetics.com/news/fda-approves-rha-dynamic-volume-for-midface-augmentation/2485309/The US Food and Drug Administration (FDA) has approved RHA® Dynamic Volume from the Teoxane RHA® Collection for cheek augmentation and correction of age-related midface contour deficiencies in adults 22 and older, Revance and Teoxane announced.
- FDA: Most PFAS in Cosmetics Lack Adequate Safety Datahttps://modernaesthetics.com/news/fda-most-pfas-in-cosmetics-lack-adequate-safety-data/2485144/The U.S. Food and Drug Administration (FDA) announced that it has released its first congressionally mandated report under the Modernization of Cosmetics Regulation Act of 2022 (MoCRA), assessing the use and safety of perfluoroalkyl and polyfluoroalkyl substances (PF
- Senolytic Skincare Platform Backed by First Peer-Reviewed Studyhttps://modernaesthetics.com/news/senolytic-skincare-platform-backed-by-first-peer-reviewed-study/2485088/Robles BioCeutics, a regenerative dermatology company focused on senolytic and stem cell–inspired approaches, has published its first peer-reviewed article in The Journal of Translational Medicine, validating the scientific basis of its proprietary skin regeneration platform. The